To enroll in the trial, please visit the ClinicalTrials.gov website.
Category: PAC-1
See story on Pretzel, a pet dog with glioma successfully treated with PAC-1.
Clinical trials on companion animals diagnosed with cancer have brought new hope to their owners—and new data for a cutting-edge cancer drug being developed by scientists at Illinois. By Mary Timmins On the day we meet Pretzel, the weather is chilly and clear in Hammond, Ind., where she lives with her owners, Donna and Dave […]
A Phase 1b clinical trial of PAC-1 for glioblastoma patients has begun
A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain. This phase Ib trial will determine if the experimental drug PAC-1 can be used safely in combination with a standard […]
The FDA grants Orphan Drug Designation to PAC-1!
Human trials of cancer drug PAC-1 continue with new investment. University of Illinois chemistry professor Paul Hergenrother, right, and veterinary clinical medicine professor Timothy Fan tested an anti-cancer compound in pet dogs that is now being used in human clinical trials.
PAC-1 shows efficacy in dog trial
Chasing cancer with dogs — Treating canine cancers is helping researchers learn more about human forms of the disease. Thunder is a middle-aged mutt with a cheery disposition. He is slim, with a black coat and white patches on his belly and toes. His owner, Jeanneen Terry from Chicago, is unsure of Thunder’s pedigree. “He could […]
The Phase 1 clinical trial of PAC-1 in human cancer patients has begun!
See listing on clinicaltrials.gov, listen to the interview, watch a PBS documentary about comparative oncology including PAC-1, and watch the CBS Chicago report.
Vanquish Oncology, Inc. announces multimillion dollar investment to move PAC-1 to human clinical trials for cancer patients.
Cancer drug tested in pet dogs is now bound for human trials. University of Illinois chemistry professor Paul Hergenrother, left, and veterinary clinical medicine professor Tim Fan led a study of an anti-cancer compound in pet dogs that is now headed for human clinical trials. Continue reading the Illinois News Bureau article.